RE:New Press Release - Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program- Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer
- The FDA supports progression-free survival as the primary endpoint of the study, with overall survival as a key secondary endpoint
- Metastatic breast cancer overall survival (OS) results to be released this H2'24